ADARx Pharmaceuticals Stock
HealthTechLooking to sell ADARx Pharmaceuticals stock or options?
ADARx Pharmaceuticals is a clinical-stage biotechnology company committed to transforming breakthrough science into life-saving therapeutics. The company provides a unique ribonucleic acid (RNA) targeting platform, which comprises oligonucleotides for inhibition, degradation, and editing, coupled with innovative oligonucleotide delivery technologies. ADARx Pharmaceuticals also maintains a robust pipeline of RNA targeting therapeutics aimed at treating a variety of diseases. These range from genetic and cardiometabolic to complement-mediated and central nervous system diseases. The company's groundbreaking approach enables patients to quickly treat incurable diseases caused by genetic mutations.
Cormorant Asset Management, Marshall Wace, BlackRock, Venrock, Bain Capital Life Sciences, T. Rowe Price Group, Ascenta Capital, Vivo Capital, Commodore Capital, TCG Crossover Management, HBM Partners, The Invus Group, OrbiMed, SR One Capital Management, Redmile Group, HBM Healthcare Investments, Lilly Asia Ventures, Sirona Capital.